Nifuroxazide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Nifuroxazide is an antibiotic indicated in the treatment of susceptible gastrointestinal infections.

Generic Name
Nifuroxazide
DrugBank Accession Number
DB13855
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 275.22
Monoisotopic: 275.054220402
Chemical Formula
C12H9N3O5
Synonyms
  • Nifuroxazide
External IDs
  • RC-27109

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAcute diarrhoea•••••••••••••••••••• ••••••••••• •••••
Used in combination to treatAmoebiasisCombination Product in combination with: Metronidazole (DB00916)••••••••••••••••••••••• ••••••• •••• ••••••
Used in combination to treatAmoebiasisCombination Product in combination with: Metronidazole benzoate (DB15759)•••••••••••••••••••• ••••••••••
Used in combination to treatAmoebiasisCombination Product in combination with: Metronidazole (DB00916)•••••••••••••••••••• ••••••••••
Used in combination to treatAmoebic liver abscessCombination Product in combination with: Metronidazole (DB00916)••••••••••••••••••••••• ••••••• •••• ••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AMEBICOL®Nifuroxazide (200 mg) + Metronidazole (300 mg)Capsule, coatedOralBIOQUIMICO PHARMAS.A.2017-05-22Not applicableColombia flag
DIARSET NX- M SUSPENSIONNifuroxazide (4 g) + Metronidazole benzoate (5 g)SuspensionOralARBOFARMA S.A.S.2007-07-30Not applicableColombia flag
DIARSET NX® M CAPSULASNifuroxazide (200 mg) + Metronidazole (600 mg)Capsule, coatedOralCOLOMPACK S.A.2014-01-10Not applicableColombia flag
FUROTIL®CAPSULASNifuroxazide (200 mg) + Metronidazole (600 mg)Capsule, coatedOralCOLOMPACK S.A.2021-09-16Not applicableColombia flag
INVERPAR® SUSPENSIÓNNifuroxazide (4 g) + Metronidazole (8 g)SuspensionOralCOLOMPACK S.A.2009-08-212020-04-15Colombia flag

Categories

ATC Codes
A07AX03 — Nifuroxazide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzoic acids and derivatives. These are organic compounds containing a carboxylic acid substituent attached to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acids and derivatives
Alternative Parents
Nitrofurans / Nitroaromatic compounds / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Carboxylic acids and derivatives / Organopnictogen compounds
show 5 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / 2-nitrofuran / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Benzoic acid or derivatives / Benzoyl / C-nitro compound / Carboxylic acid derivative / Furan / Heteroaromatic compound
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
PM5LI0P38J
CAS number
965-52-6
InChI Key
YCWSUKQGVSGXJO-NTUHNPAUSA-N
InChI
InChI=1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)/b13-7+
IUPAC Name
4-hydroxy-N'-[(1E)-(5-nitrofuran-2-yl)methylidene]benzohydrazide
SMILES
OC1=CC=C(C=C1)C(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O

References

General References
  1. INVIMA: Acta 15 (21 and 22 July 2015) [Link]
ChemSpider
4495115
BindingDB
50396177
RxNav
31782
ChEBI
135136
ChEMBL
CHEMBL244888
ZINC
ZINC000000001808
Wikipedia
Nifuroxazide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentHepatic Encephalopathy (HE)1
2, 3RecruitingTreatmentInflammatory Bowel Diseases (IBD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral200.000 mg
SuspensionOral4.000 g
SuspensionOral4.400 g
SuspensionOral
SuspensionOral4.4 g
SuspensionOral4.483 g
TabletOral
SuspensionOral60 ml
SuspensionOral4 g
TabletOral200 mg
CapsuleOral200 MG
Capsule, coatedOral200 mg
CapsuleOral100 mg
SuspensionOral200 mg
SuspensionOral4.40 g
CapsuleOral
Tablet, coatedOral
SuspensionOral
SuspensionOral200 mg/5ml
Capsule, coatedOral
Capsule, liquid filledOral
Tablet, film coatedOral
SyrupOral
CapsuleOral400.000 mg
SuspensionOral218 mg/5mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.105 mg/mLALOGPS
logP2.59ALOGPS
logP1.75Chemaxon
logS-3.4ALOGPS
pKa (Strongest Acidic)8.33Chemaxon
pKa (Strongest Basic)-1.7Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area117.97 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity68.18 m3·mol-1Chemaxon
Polarizability26 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-00di-1920000000-6aa7111b577261e72557
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-152.87921
predicted
DeepCCS 1.0 (2019)
[M+H]+155.23723
predicted
DeepCCS 1.0 (2019)
[M+Na]+162.33952
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:49 / Updated at May 21, 2021 10:23